EBIRATIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C48H73N11O10S
Molecular Weight	996.2289
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CS(=O)(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@H](CCCCN)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)NCCCCCCCCN

InChI

InChIKey=CLFHFIGNDKHDPG-MPJXNKHJSA-N

InChI=1S/C48H73N11O10S/c1-70(68,69)27-23-36(51)43(62)55-38(21-22-42(60)61)46(65)59-41(30-35-31-52-32-54-35)48(67)58-40(29-34-18-10-7-11-19-34)47(66)56-37(20-12-14-25-50)45(64)57-39(28-33-16-8-6-9-17-33)44(63)53-26-15-5-3-2-4-13-24-49/h6-11,16-19,31-32,36-41H,2-5,12-15,20-30,49-51H2,1H3,(H,52,54)(H,53,63)(H,55,62)(H,56,66)(H,57,64)(H,58,67)(H,59,65)(H,60,61)/t36-,37+,38-,39-,40-,41-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C48H73N11O10S
Molecular Weight	996.2289
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8394847 | https://www.ncbi.nlm.nih.gov/pubmed/1666179 | https://www.ncbi.nlm.nih.gov/pubmed/1663715 | https://www.ncbi.nlm.nih.gov/pubmed/8748659

Ebiratide (Hoe 427) is a peptide analog of corticotrophin (ACTH 4-9). Ebiratide is endocrinologically inert. Ebiratide is highly lipophilic and has prolonged metabolic stability. Ebiratide exerts neurotrophic properties in vivo. It also was proven to have significant effects on acetylcholine metabolism. It has been investigated in the treatment of Alzheimer's disease.

CNS Activity

Originator

Approval Year

PubMed

Title	Date	PubMed
Learning and memory processes of an ACTH4-9 analog (ebiratide; Hoe 427) in mice and rats.	1988-05-01	2843833

Sample Use Guides

In Vivo Use Guide

In an acute trial, three different dosages (60, 300, and 600 micrograms) of the endocrinologically inert but behaviorally active corticotropin 4-9 (ACTH4-9) fragment ebiratide were given to three patients with clinically probable Alzheimer's disease and five patients with a major depressive episode who were psychomotor retarded.

Route of Administration: Intravenous

In Vitro Use Guide

The 5-day treatment with ebiratide (10-100 pmol/ml) partially prevented neuronal degeneration that occurred in the cultures in which cells were sparsely plated. Ebiratide (10 pmol/ ml) increased choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) activities up to 1.5 and 1.2 times the respective control values in the sub-confluent cultures.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 06:51:59 GMT 2025` Edited by `admin` on `Wed Apr 02 06:51:59 GMT 2025`
Record UNII	CM5J1V7AUT
Record Status	`FAILED`
Record Version

Download

Name

Type

Language

ebiratide [INN]

Preferred Name

English

EBIRATIDE

Official Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2348